Introduction: Although the etiology of inflammatory bowel diseases (IBD) remains unknown, accumulating evidence suggests that the intestinal tissue damage in these disorders is due to a dynamic interplay between immune cells and non-immune cells, which is mediated by cytokines produced within the inflammatory microenvironment. Areas covered: We review the available data about the role of inflammatory cytokines in IBD pathophysiology and provide an overview of the therapeutic options to block the function of such molecules. Expert opinion: Genome studies, in vitro experiments with patients' samples and animal models of colitis, have largely advanced our understanding of how cytokines modulate the ongoing mucosal inflammation in IBD. However, not all the cytokines produced within the damaged gut seem to play a major role in the amplification and perpetuation of the IBD-associated inflammatory cascade. Indeed, while some of the anti-cytokine compounds are effective in some subgroups of IBD patients, others have no benefit. In this complex scenario, a major unmet need is the identification of biomarkers that can predict response to therapy and facilitate a personalized therapeutic approach, which maximizes the benefits and limits the adverse events.

Marafini, I., Sedda, S., Dinallo, V., Monteleone, G. (2019). Inflammatory cytokines: from discoveries to therapies in IBD. EXPERT OPINION ON BIOLOGICAL THERAPY, 19(11), 1207-1217 [10.1080/14712598.2019.1652267].

Inflammatory cytokines: from discoveries to therapies in IBD

Marafini I.
Membro del Collaboration Group
;
Dinallo V.
Membro del Collaboration Group
;
Monteleone G.
2019-01-01

Abstract

Introduction: Although the etiology of inflammatory bowel diseases (IBD) remains unknown, accumulating evidence suggests that the intestinal tissue damage in these disorders is due to a dynamic interplay between immune cells and non-immune cells, which is mediated by cytokines produced within the inflammatory microenvironment. Areas covered: We review the available data about the role of inflammatory cytokines in IBD pathophysiology and provide an overview of the therapeutic options to block the function of such molecules. Expert opinion: Genome studies, in vitro experiments with patients' samples and animal models of colitis, have largely advanced our understanding of how cytokines modulate the ongoing mucosal inflammation in IBD. However, not all the cytokines produced within the damaged gut seem to play a major role in the amplification and perpetuation of the IBD-associated inflammatory cascade. Indeed, while some of the anti-cytokine compounds are effective in some subgroups of IBD patients, others have no benefit. In this complex scenario, a major unmet need is the identification of biomarkers that can predict response to therapy and facilitate a personalized therapeutic approach, which maximizes the benefits and limits the adverse events.
Pubblicato
Rilevanza internazionale
Recensione
Esperti anonimi
Settore MED/12 - Gastroenterologia
English
Con Impact Factor ISI
Crohn’s disease; IL-12; IL-23; JAK/STAT; TNF; tofacitinib; ulcerative colitis; ustekinumab
Marafini, I., Sedda, S., Dinallo, V., Monteleone, G. (2019). Inflammatory cytokines: from discoveries to therapies in IBD. EXPERT OPINION ON BIOLOGICAL THERAPY, 19(11), 1207-1217 [10.1080/14712598.2019.1652267].
Marafini, I; Sedda, S; Dinallo, V; Monteleone, G
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/224986
Citazioni
  • ???jsp.display-item.citation.pmc??? 38
  • Scopus 65
  • ???jsp.display-item.citation.isi??? 63
social impact